Trials / Recruiting
RecruitingNCT06548529
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC
Al18F-HER2-BCH PET/CT to Predict Response in Bladder Cancer Patients Treated With HER2 ADC
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value of HER2 expression in bladder cancer patients treated with HER2 ADC
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | HER2 expression of PET imaging | Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with ADC |
Timeline
- Start date
- 2024-06-01
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
- First posted
- 2024-08-12
- Last updated
- 2024-08-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06548529. Inclusion in this directory is not an endorsement.